openPR Logo
Press release

Fortis Malar Hospital conducts a very rare heart operation on a newborn

07-08-2011 09:47 AM CET | Health & Medicine

Press release from: Fortis Hospitals

Fortis Malar Hospital

Fortis Malar Hospital

Fortis Malar Hospital today announced the successful removal of a tumor in a new born baby in the city. Leading cardiologist Dr. K R Balakrishnan, Director - Cardiac Sciences, Dr. Nandkishore Kapadia, Senior Cardio Thoracic Surgeon & Dr. Suresh Rao, HOD - Cardiac Anesthesia & Cardiac Critical Care performed a rare surgery on Baby Asiffa, 20 day old baby with a very large tumor in one of the chambers of the heart.
On becoming blue and breathless, the baby was rushed to Fortis Malar hospital where she was diagnosed with a tumor in the heart. The procedure involved administering anesthesia which was critical as the baby was just a few days old. The tumor blocking the right side of the heart lead to a collapse of the child as oxygen levels were dangerously low.
On becoming blue and breathless, the baby was rushed to Fortis Malar hospital where she was diagnosed with a tumor in the heart. The child collapsed since the tumour blocking the right side of the heart led to dangerously low oxygen levels. The procedure involved administering anesthesia which was critical as the baby was just a few days old.
The baby’s body temperature was cooled to 15 degree Celsius and the circulation was stopped and under suspended animation the tumor was completely removed. The tumor was a leiomyoma- a benign tumor (a tumor commonly seen in the uterus of women).

For the first time in the world a leiomyoma of the heart has been reported in a newborn. The baby has recovered well and can expect to lead a normal life.

About Fortis Malar Hospitals Ltd (erstwhile Malar Hospitals Ltd):
Fortis Malar Hospitals Ltd, founded in 1992, is established as one of the largest corporate hospitals in Chennai providing quality super specialty and multi specialty healthcare services. Fortis Malar Hospitals, with 180 beds, focuses on providing comprehensive medical care in the areas of cardiology and cardiac surgery, gynaecology, orthopaedics, gastroenterology, neurology, pediatrics, diabetics, and nephrology.
Fortis Malar Hospitals also has a state of the art Cath Lab and multiple dedicated cardiac operation theatres and intensive coronary care units. Several rare and complex Adult and Pediatric Cardiac surgeries, Orthopedics and Joint replacement, Neurosurgery and Plastic reconstruction surgeries have been performed in this hospital. The hospital’s Obstetrics and Gynaecology services are among the busiest in the city, performing many difficult deliveries and surgeries successfully, and are supported by a dedicated Neonatology unit. Fortis Malar Hospitals is a part of the Fortis Healthcare Network.

With 39 hospitals across the country, over 5000 beds and 48000 surgical procedures in the last year alone, Fortis is one of India's largest healthcare and Asia's fastest growing network

Fortis Hospital Seshadripuram
#65, 1st main road, Sheshadripurum,
Bengaluru-560 020
Email: enquiries@fortishospitals.in

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fortis Malar Hospital conducts a very rare heart operation on a newborn here

News-ID: 182739 • Views:

More Releases from Fortis Hospitals

7th Time Replacement on a Iragi Patient
7th Time Replacement on a Iragi Patient
Mumbai, 22nd July 2011: Setting yet another milestone in orthopedic surgery, Dr Sachin Bhonsle at Fortis Hospital Mulund performed a complicated hip replacement revision surgery on a 52 year old Iraqi lady who had undergone 6 failed hip surgeries before. Dr Sachin Bhonsle, Consultant Orthopedic Surgeon took up a challenge to perform the 6th followed by 7th revision putting the patient back on her feet. Sixth is a preparatory for

More Releases for Malar

Cutaneous Lupus Erythematosus FDA Approvals, Clinical Trials and Pipeline Insigh …
United States, Nevada, Las Vegas, DelveInsight's 'Cutaneous Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Cutaneous Lupus Erythematosus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cutaneous Lupus Erythematosus pipeline domain. Request for a detailed sample report @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Cutaneous Lupus Erythematosus Pipeline Report Over 12+ Cutaneous
Mammalian Single Cell Market Key Growth Drivers, Competitive Landscape, and Glob …
The Global Mammalian Single Cell Market is projected to witness remarkable growth through 2032, driven by advancements in single-cell analysis techniques and an increasing focus on personalized medicine and targeted therapies. The market encompasses various techniques, including single-cell RNA sequencing, single-cell ATAC sequencing, single-cell CRISPR screening, and single-cell spatial transcriptomics, catering to diverse applications in cancer research, immunology, neurobiology, developmental biology, and drug discovery. In 2023, the Mammalian Single Cell Market
Cutaneous Lupus Erythematosus FDA Approvals, Clinical Trials and Pipeline Insigh …
United States, Nevada, Las Vegas, DelveInsight's 'Cutaneous Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Cutaneous Lupus Erythematosus therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Cutaneous Lupus Erythematosus pipeline domain. Request for a detailed sample report @ https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Cutaneous Lupus Erythematosus Pipeline Report Over 12+ Cutaneous
Facial Transformation Horizon: Craniofacial Implants Market Envisaged to Reach U …
The global Craniofacial Implants Market is expected to reach US$ 114.9 million by 2033, from US$ 51.2 million in 2022. The anatomical shaped implants segment has topped the global market within the shape category, with a market share of around 29.2%, and is expected to grow at an 8.3% CAGR from 2023 to 2033. The number of falls, accidents, facial trauma, and craniofacial injuries has increased in recent decades. Though the
Rice Bran Oil Market Size, Landscape, Industry Analysis, Business Outlook, Curre …
New Jersey, United States,- Verified Market Research has recently published a research report titled, "Rice Bran Oil Market Size, and Forecast 2022-2029, Breakdown Data by Manufacturers, Key Regions, Types and Application". Primary and secondary research methodologies have been used to formulate this report. The analysis has been derived using historic and forecast. The Rice Bran Oil market is expected to thrive in terms of volume and value during the forecast
Cheek Implants Market 2018 - 2028 | Present Scenario and the Growth Prospects | …
Nowadays people are desiring to make overall facial changes for attractive features and good looks. Therefore they are moving forward towards plastic surgery procedures for facial changes. Cheek has an important role in facial looks. Cheek implants are used in plastic surgery procedures that add volume to cheek and cheekbone. Restored volume in cheekbones is helped to reconstruct the full face and return a balance between all facial features.